Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease - PAN-STAR. Prz Gastroenterol. 2018;13:6-15. [PMID: 29657605 DOI: 10.5114/pg.2018.74556]

Late-stage gem-difluoroallylation of phenol in bioactive molecules and peptides with 3,3-difluoroallyl sulfonium salts

An efficient method for the late-stage selective O-fluoroalkylation of tyrosine residues with a stable yet highly reactive fluoroalkylating reagent, 3,3-difluoroallyl sulfonium salts (DFASs), has been developed. The reaction proceeds in a mild basic aqueous buffer (pH = 11.6) with high efficiency, high biocompatibility, and excellent regio- and chemoselectivity. Various oligopeptides and phenol-containing bioactive molecules, including carbohydrates and nucleosides, could be selectively O-fluoroalkylated. The added vinyl and other functional groups from DFASs can be valuable linkers for successive modification, significantly expanding the chemical space for further bioconjugation. The synthetic utility of this protocol has been demonstrated by the fluorescently labeled anti-cancer drug and the synthesis of O-link type 1,4,7,10-tetraazacyclododecane-N,N',N,N'-tetraacetic acid-tyrosine3-octreotate (DOTA-TATE), showing the prospect of the method in medicinal chemistry and chemical biology.

A real-world retrospective study of omeprazole-domperidone combination in managing acid peptic disease with PRoton-pump Inhibitors in patients with type 2 DiabEtes mellitus (PRIDE-2)

Background

Proton-pump inhibitors, along with a prokinetic agent, are widely used to provide symptomatic relief amongst patients with acid peptic disease (APD). This article evaluates the effectiveness and safety of the omeprazole-domperidone combination amongst patients with type 2 diabetes mellitus for the management of APD.

Methods

PRIDE-2 (PRoton-pump Inhibitor in patients with type 2 DiabEtes mellitus) is a retrospective study reviewing electronic medical records of patients with type 2 diabetes mellitus and APD who were receiving the omeprazole-domperidone combination and visiting multiple Indian healthcare settings between March 2018 and April 2021. The effectiveness outcome of the therapy was evaluated in terms of resolution of APD symptoms at visit 5 (120 days after baseline visit) compared with visit 1 (baseline visit). Safety was determined in terms of reported adverse events (AEs) during the treatment period (120 days).

Results

A total of 174 patients were included in the study. The mean age of the patients was 51.5±9.6 years, with the majority (59.8%) being men. A significant proportion of patients reported relief from APD symptoms, including abdominal pain (91.6%), epigastric burning (68.7%), nausea (89.5%), flatulence (100.0%), loss of appetite (93.6%), and altered bowel movements (94.7%) (p<0.001 for each) at visit 5 compared with visit 1. No serious AEs were reported.

Conclusion

Omeprazole-domperidone combination was beneficial in providing symptomatic relief to patients with diabetes and APD. The combination therapy was well tolerated, with few reports of minor AEs.

An Evidence-Based Retrospective Study for the Management of Acid Peptic Disease With Omeprazole, a Proton Pump Inhibitor, in Indian Patients With Type 2 Diabetes Mellitus (PRIDE-1)

Background In this study, we aimed to assess the effectiveness of omeprazole therapy in the management of acid peptic disease (APD) among type 2 diabetes mellitus (T2DM) patients. Methodology In this multicenter retrospective study, electronic medical records (EMRs) of T2DM patients with APD who were prescribed omeprazole between March 2018 and April 2021 at multiple Indian healthcare settings were reviewed. The resolution of APD symptoms was assessed at visit five (120 days after the index visit) and compared to visit one (index visit). Safety was established in terms of reported adverse events during the study period. Results Overall, 174 patients were included. The majority of patients (63.8%) were males with a mean age of 48.6 ± 11.03 years. After receiving omeprazole therapy, a significant number of patients reported improvement in symptoms such as abdominal pain (98.2%), epigastric burning (74.2%), altered bowel movements (62.1%), and nausea (80.5%) (p < 0.001 for each). Complete resolution was observed in all patients who complained about flatulence (100.0%) and loss of appetite (100.0%) (p < 0.001 for each). The drug was found to be well tolerated. Conclusions Omeprazole therapy was well tolerated and highly effective in resolving APD symptoms among T2DM patients receiving fixed oral hypoglycemic agents.

Correlation of sleep quality with mental state and quality of life in elderly patients with gastroesophageal reflux

BACKGROUND

Gastroesophageal reflux disease (GERD) is one of the common diseases of the digestive system, and long-term and repeated attacks of the disease greatly affect the quality of life and sleep quality of patients. It is of important significance to improve the sleep quality and mental state of these patients to improve their treatment compliance and quality of life.

AIM

To investigate the correlation of sleep quality with mental state and quality of life in elderly patients with GERD.

METHODS

One hundred and twenty elderly patients with GERD treated at the Second Hospital of Jinhua City, Zhejiang Province from January 2018 to September 2019 were enrolled, including 70 without sleep disorders (control group) and 50 with sleep disorders (observation group). Sleep quality, mental status, and quality of life scale scores were evaluated in all patients, and Pearson and Spearman correlation analyses were performed.

RESULTS

Compared with the control group, the scores of all dimensions of the Pittsburgh Sleep Quality Index (PSQI) scale increased significantly in the observation group (P < 0.05), with the increase in the scores of time to sleep, sleep duration, and sleep disorders more prominent (P < 0.01). Compared with the control group, the scores of somatization, anxiety, depression, paranoia, force, and psychosis of the SCL-90 were significantly higher in the observation group (P < 0.05), while those of hostile, terror, and interpersonal sensitivity showed no significant change (P > 0.05). Compared with the control group, the scores of physical functioning, physical role, general health, vitality, social function, emotional function, and mental health of the SF-36 were significantly lower in the observation group (P < 0.05), while the score of bodily pain increased significantly (P < 0.05). Correlation analysis showed that the scores of the eight dimensions of the SF-36 were negatively correlated with the scores of somatization, anxiety, depression, paranoia, force, and psychosis of the SCL-90 (P < 0.05).

CONCLUSION

Sleep disorder in elderly GERD patients is an important factor affecting psychological state and quality of life, and quality of life is negatively correlated with somatization, anxiety, depression, paranoia, compulsion, and psychosis of the SCL-90. Therefore, attention should be paid to patients' mental state to improve their quality of life and sleep in clinical practice.